311 related articles for article (PubMed ID: 1370437)
21. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents.
Allavena P; Damia G; Colombo T; Maggioni D; D'Incalci M; Mantovani A
Cell Immunol; 1989 Apr; 120(1):250-8. PubMed ID: 2784721
[TBL] [Abstract][Full Text] [Related]
22. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma.
Savas B; Kerr PE; Ustun H; Cole SP; Pross HF
Anticancer Res; 1998; 18(6A):4355-61. PubMed ID: 9891492
[TBL] [Abstract][Full Text] [Related]
23. Bovine NK and LAK susceptibility is independent of class I expression on B lymphoblastoid variants.
Li W; Splitter GA
Vet Immunol Immunopathol; 1994 Jun; 41(3-4):189-200. PubMed ID: 7941303
[TBL] [Abstract][Full Text] [Related]
24. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Bonavida B; Nio Y; Yoshida O
Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
[TBL] [Abstract][Full Text] [Related]
25. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of human natural killer cell activity by recombinant interleukin-2 towards multidrug-resistant human epidermoid carcinoma.
Ades EW; Bosse D; Pruckler J
Pathobiology; 1990; 58(2):84-7. PubMed ID: 1972884
[TBL] [Abstract][Full Text] [Related]
27. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
Fierro MT; Liao XS; Lusso P; Bonferroni M; Matera L; Cesano A; Lista P; Arione R; Forni G; Foa R
Leukemia; 1988 Jan; 2(1):50-4. PubMed ID: 3257539
[TBL] [Abstract][Full Text] [Related]
29. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity.
Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A
Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327
[TBL] [Abstract][Full Text] [Related]
30. Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.
Vu UE; Pavletic ZS; Wang X; Joshi SS
Leuk Lymphoma; 2000 Nov; 39(5-6):573-82. PubMed ID: 11342340
[TBL] [Abstract][Full Text] [Related]
31. CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.
Komatsu F; Kajiwara M
Oncol Res; 2000; 12(1):17-24. PubMed ID: 11061342
[TBL] [Abstract][Full Text] [Related]
32. Lymphokine-activated killer cell functions in patients with leukemic B-lymphoproliferative diseases.
van der Harst D; Brand A; van Luxemburg-Heys SA; Kooy-Winkelaar EM; van Rood JJ
Blood; 1989 Nov; 74(7):2464-70. PubMed ID: 2804374
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
[TBL] [Abstract][Full Text] [Related]
34. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
[TBL] [Abstract][Full Text] [Related]
35. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytolysis.
Lobo PI; Chang MY; Mellins E
Immunology; 1996 Aug; 88(4):625-9. PubMed ID: 8881767
[TBL] [Abstract][Full Text] [Related]
37. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
38. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
39. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms.
Bean P; Mazumder A
Immunobiology; 1992 Jun; 185(1):63-77. PubMed ID: 1398742
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells.
Kimmig A; Gekeler V; Neumann M; Frese G; Handgretinger R; Kardos G; Diddens H; Niethammer D
Cancer Res; 1990 Nov; 50(21):6793-9. PubMed ID: 1698543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
